A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents

Saudi Medical Journal

Volumn 29, Issue 8, 2008, Pages 1130-1134

  Arman, Soroor ^a   Sadramely, Mohammad R ^a   Nadi, Mortaza ^a   Koleini, Navid ^a,b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; PLACEBO; RISPERIDONE; ANTIDIABETIC AGENT; NEUROLEPTIC AGENT;

ARTICLE; BLOATING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD PSYCHIATRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; ENURESIS; EVENING DOSAGE; FEMALE; HUMAN; IRAN; MALE; MORNING DOSAGE; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SCHOOL CHILD; SIDE EFFECT; VOMITING; WEIGHT CHANGE; WEIGHT CONTROL; WEIGHT GAIN; CHILD; DRUG EFFECT;

ANTIPSYCHOTIC AGENTS; CHILD; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; RISPERIDONE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 56149090570     PISSN: 03795284     EISSN: 16583175     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA. A randomized, double-blind, placebo-controlled trial of metformin treatment or weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Am J Psychiatry 2006; 163: 2072-2079.
2. Morrison JA, Cottingham EM,. Barton BA, Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002; 159: 655-657.
3. Theleritis CG, Papadimitriou GN, Papageorgiou CC, Dikeos DG, Masdrakis V, Kostoulas C, et al. Excessive weight gain after remission of depression in schizophrenic patient treated with risperidone: Case report. BMC Psychiatry 2006; 6: 37.
4. Saddichha S, Ameen S, Akhtar S. Predictors of Antipsychotic-Induced Weight Gain in First-Episode Psychosis: Conclusions From a Randomized, Double-Blind, Controlled Prospective Study of Olanzapine, Risperidone, and Haloperidol. J Clin Psychopharmacol 2008; 82: 27-31.
5. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, et al. Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophr Bull 2008; 34: 60-71. Epub 2007 Oct 8.
6. Fedorowicz VJ, Fombonne E. Metabolic side effects of typical antipsychotics in children: A literature review. J Psychopharmacol 2005; 19: 533-550.
7. Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 2004; 24: 429-436.
8. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: A frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005 Jan; 62: 19-28.
9. Wu RR, Zhao JP, Liu ZN, Zhai JG, Guo XF, Guo WB, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl) 2006; 186: 572-578. Epub 2006 Apr 7.
10. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia, Arch Gen Psychiatry 2002; 59: 337-345.
11. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003; 64: 598-604.
12. Henderson DC, Fan X, Copeland PM, Borba CP, Daley TB, Nguyen DD, et al. A double-blind, placebo-controlled trial of sibutramine for clozapine-associated weight gain. Acta Psychiatr Scand 2007; 115: 101-105.
13. Allison DB, Mackell JA, McDonnell DD: The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54: 565-567.
14. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry 1999 Nov; 156: 1686-1696.
15. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: A multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group. Br J Psychiatry 1995; 712-726.
16. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223. Epub 2005 Sep 19.
17. Baptista T, Rangel N, Fernández V, Carrizo E, El Fakih Y, Uzcátegui E, et al. Metformin a an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial. Schizophr Res 2007; 93: 99-108. Epub 2007 May 8.
18. Faulkner G, Cohn T, Remington G. Intervention to reduce weight gain in schizophrenia. Schizophr Bull 2007; 33: 654-656. Epub 2007 Apr 21.
19. Freemark M, Bursey D. The effects of merformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107: E55.
20. Chen Ch, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 925-931. Epub 2007 Nov 17.
21. Baptista T, Martínez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, et al. Metformin for prevention of weight gain and insulin resistance with olanzapine: A double-blind placebo-controlled trial. Can J Psychiatry 2006; 51: 192-196.
22. Baptista T, Uzcátegui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, et al. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: A 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 2008; 159: 250-253. Epub 2008 Apr 18.
23. Ozenoglu A, Ugurlu S, Balci H, Eker E. Nutritional approach to metabolic changes arising out of schizophrenia therapy: Case report. Intern Med 2007; 1213-1218. Epub 2007 Aug 2.
24. Dibben CR, Kalavalapalli SS, Linnington HE, Hynes FA, Dinneen SF, Adler AI, et al. Diabetes associated with atypical antipsychotic treatment may be severe but reversible: Case report. Int J Psychiatry Med 2005; 35: 307-311.
25. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, et al. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study. Am J Psychiatry 2008; 165: 352-358. Epub 2008 Feb 1.
26. Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacospsychiatry 2002; 35: 205-219.
27. Wu RR, Zhao JP, Jin H, Shao P, Fang MS, Guo XF, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced wieght gain: A randomized controlled trail. JAMA 2008; 299: 185-193.
28. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63: 425-433.